Osivax announces that the Belgian health authority approved the initiation of a first-in-human clinical trial evaluating the safety and immunogenicity of OVX836 in healthy volunteers Lyon, France – June 4, 2018 – Osivax, a clinical stage biopharmaceutical company currently focused on the development of a universal influenza vaccine candidate, announced today that the Belgian health authority …
Archives de la catégorie : 2018
Osivax strengthens its collaboration with the German Cancer Research Center (DKFZ)
As DKFZ’s HPV vaccine candidate based on Osivax’s technology platform (OVX313) reports promising pre-clinical results, a second license agreement was signed Lyon, France – April 17, 2018 – Osivax, a biopharmaceutical company currently focused on the development of a universal influenza vaccine candidate, announced today the reinforcement of its collaboration with the world-renowned German Cancer Research …
Osivax appoints Prof. Jeffrey Almond, pre-eminent Vaccinologist, as Chairman of its Scientific Advisory Board
Prof. Almond’s appointment will strengthen Osivax’s capacities to drive, position and prioritize pipeline development and especially OVX836, a broad-spectrum influenza vaccine Lyon, France – February 19th, 2018 – Osivax, a biopharmaceutical company currently focused on the development of a breakthrough influenza vaccine, announced today that the Company is strengthening its management team with the appointment of …
Osivax appoints Dr. Delphine Guyon-Gellin as Chief Business Development Officer
This recruitment brings strategic capabilities to drive the development of Osivax’s lead candidate, a breakthrough influenza vaccine Lyon, France – January 24th, 2018 – Osivax, a biopharmaceutical company currently focused on the development of a breakthrough influenza vaccine, announced today that the Company is strengthening its management team with the appointment of Dr. Delphine Guyon-Gellin as …